What is Arocell?
Saving lives with diagnostics.
– We provide knowledge to decision.
– AroCell Group consist of AroCell AB and IDL Biotech.
IDL Diagnostics strengthens its presence in Indonesia through the SISP partnership
Last week, IDL Diagnostics participated in the Sweden-Indonesia Sustainability Partnership (SISP) 2025, organized by Business Sweden and the Swedish Embassy in Indonesia. The Sweden-Indonesia Sustainability Partnership (SISP) is a platform designed to foster...
EAU 2025
We attended the European Association of Urology #EAU25 in Madrid last weekend. Many valuable insights and great discussion with urologists from all over the world on the latest urology practice and how our products can contribute in improving cancer care. #EAU25 is...
AroCell’s Innovations and Future Prospects Presented at Redeye’s Event
AroCell participated at Redeye's Technology & Life Science day on December 3rd. CEO Anders Hultman presented the latest developments and future prospects of the company. The presentation is now available for listening below. AroCell: CEO Anders Hultman presenterar...
UBC® Rapid | Bladder Cancer detection
A powerful Doctors-office test (Point-of-Care), for aid in the diagnosis and monitoring of bladder cancer. Read more about UBC® Rapid
TUBEX® TF | Rapid Typhoid Detection
A rapid and sensitive in vitro diagnostic test for detection of acute typhoid fever, a disease caused by Salmonella typhi. Read more about TUBEX® TF
TK 210 ELISA | Cell Proliferation Biomarker
The AroCell TK 210 ELISA kit used for therapy response in subjects with many forms of cancer including several solid tumors. Read more about TK 210 ELISA
Tumor markers licensed to strategic partners
Arocell is constantly building partnerships for establishing projects and developing new products to expand its portfolio. Read More about tumor markers
Press Releases
About us
We provide knowledge to decision.
IDL Diagnosticsis a Swedish diagnostics company with the vision to improve the monitoring of oncological and bacterial diseases. We have a broad product portfolio of IVD tests that deliver high-value clinical information for the detection of diseases.
Investors
We are listed on NASDAQ First North Growth Market.
We want to be the obvious choice within our segment in the markets where we are established. The market for our products is large and we are a smaller player with significant growth potential so far. IDL Diagnostics is unique for a company of this size.
